Phase III
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
The job cuts were announced as part of an organizational streamlining initiative that will refocus resources toward the company’s highest-value activities.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
The approval was based on data from a broad clinical program of 1,854 adults with insomnia conducted at more than 160 clinical sites in 18 countries.
PRESS RELEASES